glp-1 agonist cardiovascular outcomes The effects of receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action Targeting the weight within: obesity
Description
Inflammatory proteins associated with Alzheimers disease reduced by a GLP1 receptor agonist: A post hoc analysis of the EXSCEL randomized placebo controlled trial
doi: 10.1056/NEJMoa2107519
While GLP-1RAs are most effective in individuals with a BMI over 30, their alcohol-reducing effects are not necessarily tied to body weight
Frlund is a co-founder of Ceremedy
Only the most aggressive growth investors should probably consider this one.
Capehorn MS, Catarig AM, Furberg JK, Janez A, Price HC, Tadayon S, Vergs B, Marre M
